Next-Generation Models for Chronic Inflammation and Fibrosis
Precision In-Vivo Platforms for Mechanistic Insights and Tissue Remodeling ,Empowering Research with High-Fidelity Preclinical Models
“Uncovering the Mechans of Chronic Inflammation and Fibrosis”
Our company is a life science organization specializing in preclinical evaluation and validation of compounds that target chronic inflammatory and fibrotic processes.
Using a panel of in vivo models for these conditions, including our proprietary N-IF mouse model, which closely replicates chronic inflammation and fibrosis, we provide effect testing and assessment of novel interventions aimed at modulating these processes.
Built on extensive expertise in immunology, inflammation, and fibrosis research, our team offers efficient and flexible management of preclinical evaluation projects, delivering high-quality, scientifically robust insights into the efficacy of new experimental approaches.
Improvement of medical treatments
Funded research projects
Customer satisfaction rate
Millions de cellules régénérées
What is the N-IF mouse ?
the N-IF mouse is a naturally developing model for inflammation and fibrosis It starts with chronic low-grade inflammation, Which then triggers fibrotic tissue formation (scarring), Seen in organs like the liver, kidney, and lungs. This model is valuable because it mimics the natural biological progression of many human inflammatory and fibrotic conditions, providing a realistic platform for testing how potential interventions might affect these processes.
What Is Chronic Inflammation?
Chronic inflammation is a prolonged and dysregulated immune response that persists for weeks, months, or even years. Unlike acute inflammation which is a short, protective reaction chronic inflammation can become harmful, leading to tissue injury and impaired function. It is often triggered by persistent infections, autoimmune reactions, or long-term exposure to irritants such as pollutants or metabolic stress.
The Link Between Inflammation and Fibrosis
Fibrosis is the excessive accumulation of extracellular matrix (ECM) components, particularly collagen, as a result of prolonged tissue repair and scarring processes. When chronic inflammation continues unchecked, immune cells continuously release cytokines and growth factors like TGF-β, IL-6, and TNF-α. These molecules activate fibroblasts and myofibroblasts, promoting ECM deposition and ultimately leading to fibrosis.
Disorders Involving Chronic Inflammation and Fibrosis
Chronic inflammation and fibrosis are hallmarks of several major disorders, including:
- Liver fibrosis and cirrhosis (caused by hepatitis or alcohol abuse)
- Pulmonary fibrosis (idiopathic pulmonary fibrosis)
- Renal fibrosis (chronic kidney disorder)
- Cardiac fibrosis (following myocardial infarction)
- Systemic sclerosis and rheumatoid arthritis
Therapeutic Strategies
Modern therapeutic approaches aim to:
- Reduce inflammation (targeting cytokine pathways)
- Inhibit fibroblast activation (TGF-β or PDGF inhibitors)
- Promote ECM degradation ( MMP activators)
- Use gene therapy and precision medicine to correct underlying molecular triggers
Chronic Inflammation and Fibrosis in the Liver
The liver is highly resilient but also particularly vulnerable to chronic inflammation, which can lead to fibrosis and, in severe cases, cirrhosis or liver failure.
Causes of Chronic Liver Inflammation
Chronic liver inflammation can arise from various sources:
- Viral infections: Hepatitis B and C viruses cause persistent immune activation in hepatocytes.
- Alcohol abuse: Long-term alcohol consumption damages liver cells, triggering inflammatory pathways.
- Non-alcoholic fatty liver disorder (NAFLD) / NASH: Fat accumulation in the liver leads to oxidative stress and inflammatory responses.
- Autoimmune hepatitis: The immune system attacks liver tissue, sustaining inflammation.
- Drug-induced liver injury: Certain medications or toxins chronically irritate liver cells.
Clinical Impact
- Early-stage fibrosis: Often asymptomatic but detectable via biomarkers or imaging.
- Advanced fibrosis / cirrhosis: Can lead to portal hypertension, jaundice, ascites, and risk of hepatocellular carcinoma.
- Metabolic consequences: Chronic liver inflammation affects glucose and lipid metabolism, contributing to systemic
Nos derniers contenus
Découvrez les nouveautés dans notre entreprise !
Discover Our Products !
“Innovating for the Science of Tomorrow”
Join our mission to advance understanding of chronic inflammation and fibrotic processes. We are dedicated to developing innovative preclinical solutions that transform research and accelerate discoveries in tissue remodeling and organ inflammation.